J. Fred Pritchard

413 total citations
7 papers, 285 citations indexed

About

J. Fred Pritchard is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, J. Fred Pritchard has authored 7 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Molecular Biology, 2 papers in Oncology and 2 papers in Pharmacology. Recurrent topics in J. Fred Pritchard's work include Liver Disease and Transplantation (2 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers) and Pharmaceutical Economics and Policy (2 papers). J. Fred Pritchard is often cited by papers focused on Liver Disease and Transplantation (2 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers) and Pharmaceutical Economics and Policy (2 papers). J. Fred Pritchard collaborates with scholars based in United States and Netherlands. J. Fred Pritchard's co-authors include Mallé Jurima‐Romet, Mitchell N. Cayen, Mark L. J. Reimer, David Hermann, J. Robert Powell, Stanley W. Carson, Henry R. Lesesne, George E. Dukes, William D. Figg and Lawrence J. Hak and has published in prestigious journals such as Nature Reviews Drug Discovery, British Journal of Cancer and Journal of Pharmaceutical and Biomedical Analysis.

In The Last Decade

J. Fred Pritchard

7 papers receiving 271 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Fred Pritchard United States	6	111	46	45	39	32	7	285
Joan D. Ellis United States	14	129 1.2×	71 1.5×	31 0.7×	81 2.1×	29 0.9×	19	483
Carlo Sensenhauser United States	11	126 1.1×	73 1.6×	140 3.1×	41 1.1×	19 0.6×	12	352
Ian Knemeyer United States	8	163 1.5×	89 1.9×	44 1.0×	17 0.4×	36 1.1×	9	500
Shirin Bruderer Switzerland	15	182 1.6×	39 0.8×	52 1.2×	12 0.3×	26 0.8×	26	620
Kara Pearson United States	8	107 1.0×	23 0.5×	62 1.4×	33 0.8×	47 1.5×	15	311
Takahiro Murai Japan	10	83 0.7×	58 1.3×	142 3.2×	20 0.5×	20 0.6×	27	354
Muriel Saulnier United States	9	145 1.3×	38 0.8×	55 1.2×	70 1.8×	15 0.5×	13	439
Bolette Husman Sweden	13	178 1.6×	15 0.3×	11 0.2×	52 1.3×	48 1.5×	19	483
Cerys Lovatt United Kingdom	6	148 1.3×	51 1.1×	116 2.6×	24 0.6×	9 0.3×	6	298
Shien Zou China	14	155 1.4×	37 0.8×	33 0.7×	31 0.8×	19 0.6×	30	481

Countries citing papers authored by J. Fred Pritchard

Since Specialization

Citations

This map shows the geographic impact of J. Fred Pritchard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Fred Pritchard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Fred Pritchard more than expected).

Fields of papers citing papers by J. Fred Pritchard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Fred Pritchard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Fred Pritchard. The network helps show where J. Fred Pritchard may publish in the future.

Co-authorship network of co-authors of J. Fred Pritchard

This figure shows the co-authorship network connecting the top 25 collaborators of J. Fred Pritchard. A scholar is included among the top collaborators of J. Fred Pritchard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Fred Pritchard. J. Fred Pritchard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Pritchard, J. Fred. (2008). Risk in CNS drug discovery: focus on treatment of Alzheimer's Disease. BMC Neuroscience. 9(S3). S1–S1. 4 indexed citations

2.

Pritchard, J. Fred, et al.. (2003). Making Better Drugs: Decision Gates in Non-Clinical Drug Development. Nature Reviews Drug Discovery. 2(7). 542–553. 173 indexed citations

3.

Wu, W. N., et al.. (1999). In vitro metabolic products of RWJ-34130, an antiarrythmic agent, in rat liver preparations. Journal of Pharmaceutical and Biomedical Analysis. 20(4). 687–695. 5 indexed citations

4.

Schellens, JHM, G.J. Creemers, Paul Wissel, et al.. (1997). The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. British Journal of Cancer. 76(7). 946–951. 24 indexed citations

5.

Figg, William D., George E. Dukes, J. Fred Pritchard, et al.. (1996). Pharmacokinetics of Ondansetron in Patients with Hepatic Insufficiency. The Journal of Clinical Pharmacology. 36(3). 206–215. 36 indexed citations

6.

Figg, William D., George E. Dukes, Henry R. Lesesne, et al.. (1995). Comparison of Quantitative Methods to Assess Hepatic Function: Pugh's Classification, Indocyanine Green, Antipyrine, and Dextromethorphan. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 15(6). 693–700. 23 indexed citations

7.

Pritchard, J. Fred, et al.. (1988). Teratogenicity of N‐(4‐hydroxyphenyl) ‐all‐trans‐retinamide in rats and rabbits. Teratogenesis Carcinogenesis and Mutagenesis. 8(1). 1–11. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact